Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia

Experimental Hematology

Volumn 36, Issue 12, 2008, Pages 1642-1647

  Mossuz, Pascal ^a,b   Arlotto, Marie ^b   Hermouet, Sylvie ^c   Bouamrani, Ali ^b   Lippert, Eric ^d   Girodon, François ^e   Dobo, Irène ^f   Vincent, Praloran ^d   Cahn, Jean Yves ^a   Berger, François ^b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; JANUS KINASE 2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; HUMAN; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

AMINO ACID SUBSTITUTION; BLOOD PROTEINS; FEMALE; GENETIC DISEASES, INBORN; HUMANS; JANUS KINASE 2; MALE; MUTATION, MISSENSE; PHENOTYPE; POLYCYTHEMIA VERA; PROTEOME; PROTEOMICS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 55549119584     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.07.013     Document Type: Article

References (24)

1. Levine R.L., Pardanani A., Tefferi A., and Gilliland G. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev 7 (2007) 673-683
2. Campbell P.J., Scott L.M., Buck G., et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2-V617F mutation status: a prospective study. Lancet 366 (2005) 1945-1953
3. V6127F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110 (2007) 840-846
4. Kittur J., Knudson R.A., Lasho T.L., et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109 (2007) 2279-2284
5. Lippert E., Boissinot M., Kralovics R., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 108 (2006) 1865-1867
6. V6127F allele burden on phenotype in essentiel thrombocythemia. Haematologica 93 (2008) 41-48
7. Thadikkaran L., Siegenthaler M.A., Crettaz D., Queloz P.A., Schneider P., and Tissot J.D. Recent advances in blood related proteomics. Proteomics 5 (2005) 3019-3034
8. Hegedus C.M., Gunn L., Skibola C.F., et al. Proteomic analysis of childhood leukaemia. Leukemia 19 (2005) 1713-1718
9. Cussac D., Picheeaux C., Colomba A., et al. Proteomic analysis of anaplastic lymphoma cell lines: identification of potential tumour markers. Proteomics 6 (2006) 3210-3222
10. Zheng P.Z., Wang K.K., Zhang Q.H., et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apopotosis of promyelocytic leukemia. PNAS 102 (2005) 7653-7658
11. Albitar M., Potts S.J., Giles F., et al. Proteomic-based prediction of clinical behaviour in adult acute lymphoblastic leukaemia. Cancer 106 (2006) 1587-1594
12. Cui J.W., Wang J., He K., et al. Proteomic analysis of human leukemia cells: insight into their classification. Clin Cancer Res 10 (2004) 6887-6896
13. Paradis V., Degos F., Dargere D., et al. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. Hepatology 41 (2005) 40-47
14. Zhang Z., Bast R.C., Yu Y., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage of ovarian cancer. Cancer Res 64 (2004) 5882-5890
15. Kwak J.Y., Ma T.Z., Yoo M.J., et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 32 (2004) 836-842
16. Mossuz P., Girodon F., Donnard M., et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 89 (2004) 1194-1198
17. Mossuz P., Bouamarani A., Brugiere S., et al. Apolipoprotein A1: A new serum marker correlated to JAK2-V617F proportion at diagnosis in patients with polycythemia vera. Proteomics Clin Appl 1 (2007) 1605-1612
18. V6127F positive myeloproliferative disease. Cancer Res 66 (2006) 11156-11165
19. Lacout C., Pisani D.F., Tulliez M., et al. JAK2-V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood 108 (2006) 1652-1660
20. Tiedt R., Shen H.H., Sobas M.A., et al. Ratio of mutant JAK2-V617F to wild type Jak2 determines the MPD phenotypes in transgenic mice. Blood 111 (2007) 3931-3940
21. Scott L.M., Scott M.A., Campbell P.J., and Green A.R. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not n essential thrombocythemia. Blood 108 (2006) 2435-2437
22. Yamamoto G., Nannya Y., Kato M., et al. Highly sensitive method for genome wide detection of allelic composition in non-paired, primary tumor specimens by use of affymetrix single nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81 (2007) 114-126
23. Boissinot M., Garand R., Hamidou M., and Hermouet S. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood 108 (2006) 1781-1782
24. Boissinot M., Lippert E., Girodon F., et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation in patients with splanchnic vein thrombosis and normal or low hematocrit and platelet counts. Blood 108 (2006) 3223-3224